StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
121
This month
2
This year
3
Publishing Date
2023 - 08 - 25
2
2023 - 01 - 25
2
2022 - 10 - 12
2
2022 - 06 - 29
2
2022 - 04 - 14
1
2022 - 04 - 05
1
2022 - 04 - 04
1
2022 - 04 - 01
1
2022 - 03 - 31
2
2022 - 03 - 15
1
2022 - 02 - 14
1
2022 - 02 - 08
1
2022 - 01 - 24
1
2021 - 12 - 22
1
2021 - 11 - 17
1
2021 - 11 - 04
1
2021 - 10 - 28
2
2021 - 10 - 27
1
2021 - 10 - 25
1
2021 - 10 - 12
1
2021 - 10 - 11
1
2021 - 09 - 30
1
2021 - 09 - 28
1
2021 - 09 - 27
1
2021 - 09 - 24
1
2021 - 09 - 22
1
2021 - 09 - 08
1
2021 - 09 - 07
2
2021 - 09 - 01
1
2021 - 08 - 25
1
2021 - 08 - 23
1
2021 - 08 - 12
1
2021 - 08 - 11
1
2021 - 08 - 10
1
2021 - 08 - 05
1
2021 - 07 - 29
1
2021 - 07 - 27
1
2021 - 07 - 22
1
2021 - 07 - 12
2
2021 - 07 - 06
1
2021 - 06 - 29
1
2021 - 06 - 24
1
2021 - 06 - 22
1
2021 - 06 - 17
1
2021 - 06 - 09
1
2021 - 06 - 03
1
2021 - 06 - 01
1
2021 - 05 - 24
1
2021 - 05 - 17
1
2021 - 05 - 13
1
2021 - 05 - 12
1
2021 - 05 - 03
1
2021 - 04 - 27
2
2021 - 04 - 13
1
2021 - 04 - 08
1
2021 - 03 - 23
1
2021 - 03 - 19
1
2021 - 03 - 17
2
2021 - 03 - 16
1
2021 - 03 - 15
2
Sector
Communications
9
Energy minerals
1
Finance
2
Health technology
121
Manufacturing
2
Technology services
1
Tags
Alliances
5
Antiviral
6
Application
7
Asco
2
Biocanada
2
Breast cancer
3
Canada
3
Cancer
32
Cell
8
Cell carcinoma
4
Children
5
China
2
Chmp
3
Clinical-trials-phase-ii
3
Clinical-trials-phase-iii
17
Collaboration
2
Commercialization
2
Conference
12
Covid
8
Covid-19
2
Disease
7
Drug
3
Earnings
8
Ervebo
2
Europe
3
Events
11
Fda
17
Fda approval
3
Health
5
Hiv
6
Keytruda
33
License
6
Lung
6
Lynparza
3
Melanoma
3
Merck
19
Molnupiravir
10
People
4
Pharm-country
10
Pharma
3
Pharmaceutical
19
Phase 3
10
Plus
10
Pneumococcal
4
Positive
4
Product-news
5
Prostate cancer
5
Regulatory
20
Renal
5
Research
6
Results
9
Review
4
Risk
6
Sales
6
Therapy
12
Treatment
26
Trial
21
Trials
3
Update
5
Vaccine
6
Entities
Amicus therapeutics, inc.
1
Astellas pharma inc
1
Bridgebio pharma, inc.
1
Dare bioscience, inc.
1
Eli lilly and company
1
Exxon mobil corporation
1
Gilead sciences, inc.
2
Glaxosmithkline plc
1
Ibio, inc.
1
Imago biosciences inc
1
Imv inc.
2
Johnson & johnson
1
Logicbio therapeutics, inc.
1
Lumos pharma, inc.
2
Merck & company, inc.
121
Moderna, inc.
2
Morgan stanley
2
Nutriband inc.
1
Orange
9
Rani therapeutics holdings inc class a
1
Sanofi
5
Seagen inc.
1
Veeva systems inc.
1
Symbols
AAPL
57
ABB
65
ABBV
58
ABLZF
51
ABT
78
AEM
64
ARVL
212
BBIO
60
BDX
80
BGNE
51
BKYI
63
BMY
108
CNC
49
CSIQ
68
CSTL
67
DHR
48
DPRO
65
ERIC
82
F
57
FCN
108
FNCTF
474
GE
66
GOLD
50
GSK
74
HON
93
HUBS
458
IBM
48
INTC
50
J
52
JNJ
352
LLY
173
LMT
50
LTUM
121
MDT
71
MMM
54
MRK
121
MRNA
61
MS
385
MSFT
86
NEE
49
NVO
65
NVS
83
NVSEF
68
ORCL
122
PFE
90
PKX
51
PPRUF
68
PPRUY
68
PSN
58
REGN
51
SAP
80
SAPGF
65
SNY
345
SNYNF
258
TECH
50
TFX
56
TMO
76
TRU
83
VZ
57
WIMI
63
Exchanges
Amex
1
Nasdaq
25
Nyse
121
Crawled Date
2023 - 08 - 25
2
2023 - 01 - 25
2
2022 - 10 - 12
2
2022 - 06 - 29
2
2022 - 04 - 14
1
2022 - 04 - 05
1
2022 - 04 - 04
1
2022 - 04 - 01
1
2022 - 03 - 31
2
2022 - 03 - 15
1
2022 - 02 - 14
1
2022 - 02 - 08
1
2022 - 01 - 24
1
2021 - 12 - 22
1
2021 - 11 - 17
1
2021 - 11 - 04
1
2021 - 10 - 28
2
2021 - 10 - 27
1
2021 - 10 - 25
1
2021 - 10 - 12
1
2021 - 10 - 11
1
2021 - 09 - 30
1
2021 - 09 - 28
1
2021 - 09 - 27
1
2021 - 09 - 24
1
2021 - 09 - 22
1
2021 - 09 - 08
1
2021 - 09 - 07
2
2021 - 09 - 01
1
2021 - 08 - 25
1
2021 - 08 - 23
1
2021 - 08 - 12
1
2021 - 08 - 11
1
2021 - 08 - 10
1
2021 - 08 - 05
1
2021 - 07 - 29
1
2021 - 07 - 27
1
2021 - 07 - 22
1
2021 - 07 - 12
2
2021 - 07 - 06
1
2021 - 06 - 29
1
2021 - 06 - 24
1
2021 - 06 - 22
1
2021 - 06 - 17
1
2021 - 06 - 09
1
2021 - 06 - 03
1
2021 - 06 - 01
1
2021 - 05 - 24
1
2021 - 05 - 17
1
2021 - 05 - 13
1
2021 - 05 - 12
1
2021 - 05 - 03
1
2021 - 04 - 27
2
2021 - 04 - 13
1
2021 - 04 - 08
1
2021 - 03 - 23
1
2021 - 03 - 19
1
2021 - 03 - 17
2
2021 - 03 - 16
1
2021 - 03 - 15
2
Crawled Time
00:00
3
01:00
4
05:00
1
10:00
1
11:00
43
12:00
121
12:15
4
12:20
14
12:30
13
12:40
1
13:00
25
13:15
3
13:20
6
13:30
8
14:00
15
14:20
2
14:21
1
14:24
1
14:30
5
15:00
10
15:30
1
16:00
8
17:00
2
18:00
7
19:00
7
19:01
1
19:47
1
20:00
4
21:00
7
22:00
7
23:00
11
Source
www.biospace.com
120
www.prnewswire.com
1
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
symbols :
Mrk
crawled time :
12:00
save search
Merck Initiates Phase 3 Clinical Trial of MK-1084, an Investigational Oral KRAS G12C Inhibitor, in Combination with KEYTRUDA® (pembrolizumab) for First-Line Treatment of Certain Patients With Metastatic Non-Small Cell Lung Cancer
Published:
2024-04-04
(Crawled : 12:00)
- biospace.com/
MRK
|
$127.0
0.1%
-1.21%
7.1M
|
Health Technology
|
-2.7%
|
O:
0.24%
H:
0.08%
C:
-2.42%
mk-1084
keytruda
lung
merck
cancer
cell
treatment
trial
Merck to Hold First-Quarter 2024 Sales and Earnings Conference Call April 25
Published:
2024-04-01
(Crawled : 12:00)
- biospace.com/
MRK
|
$127.0
0.1%
-1.21%
7.1M
|
Health Technology
|
-3.78%
|
O:
-0.23%
H:
0.19%
C:
-0.52%
sales
conference
merck
Merck Provides Update on Phase 3 KEYLYNK-006 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus Maintenance LYNPARZA® (olaparib) for Certain Patients With Metastatic Nonsquamous Non-Small Cell Lung Cancer
Published:
2024-03-21
(Crawled : 12:00)
- biospace.com/
MRK
|
$127.0
0.1%
-1.21%
7.1M
|
Health Technology
|
2.54%
|
O:
-0.13%
H:
0.4%
C:
-0.06%
ylynk-006
keytruda
lung
merck
update
cancer
cell
trial
plus
Merck Receives Positive EU CHMP Opinion for PREVYMIS® for Prevention of CMV Disease in High-Risk Adult Kidney Transplant Recipients and Extended 200-Day Dosing in Adult HSCT Recipients at Risk for Late CMV Infection and Disease
Published:
2023-10-17
(Crawled : 12:00)
- biospace.com/
MRK
|
$127.0
0.1%
-1.21%
7.1M
|
Health Technology
|
21.95%
|
O:
-0.13%
H:
0.47%
C:
0.16%
prevymis
disease
chmp
kidney
merck
positive
infection
risk
European Commission Approves KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adults With Non-Small Cell Lung Cancer at High Risk of Recurrence Following Complete Resection and Platinum-Based Chemotherapy
Published:
2023-10-16
(Crawled : 12:00)
- biospace.com/
MRK
|
$127.0
0.1%
-1.21%
7.1M
|
Health Technology
|
22.1%
|
O:
0.18%
H:
1.12%
C:
-0.06%
keytruda
lung
cancer
cell
treatment
risk
Merck Announces Pivotal KEYNOTE-671 Trial Meets Dual Primary Endpoint of Overall Survival (OS) in Resectable Stage II, IIIA or IIIB Non-Small Cell Lung Cancer (NSCLC)
Published:
2023-10-10
(Crawled : 12:00)
- biospace.com/
MRK
|
$127.0
0.1%
-1.21%
7.1M
|
Health Technology
|
21.53%
|
O:
-0.17%
H:
0.13%
C:
-0.68%
ynote-671
lung
merck
cancer
cell
trial
Merck Receives Priority Review from FDA for New Biologics License Application for Sotatercept, an Activin Signaling Inhibitor to Treat Adults with Pulmonary Arterial Hypertension (PAH)
Published:
2023-09-28
(Crawled : 12:00)
- biospace.com/
MRK
|
$127.0
0.1%
-1.21%
7.1M
|
Health Technology
|
22.19%
|
O:
0.61%
H:
0.38%
C:
-0.26%
fda
license
merck
review
treat
hypertension
application
Merck and Eisai Provide Update on Two Phase 3 Trials Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Patients With Certain Types of Metastatic Non-Small Cell Lung Cancer
Published:
2023-09-22
(Crawled : 12:00)
- biospace.com/
MRK
|
$127.0
0.1%
-1.21%
7.1M
|
Health Technology
|
18.99%
|
O:
0.46%
H:
0.0%
C:
-0.82%
LLY
|
News
|
$732.2
-1.81%
0.18%
2.1M
|
Health Technology
|
33.05%
|
O:
-2.93%
H:
1.22%
C:
0.32%
keytruda
lung
merck
update
cancer
cell
trials
plus
FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Concurrent Chemoradiotherapy as Treatment for Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer
Published:
2023-09-20
(Crawled : 12:00)
- biospace.com/
MRK
|
$127.0
0.1%
-1.21%
7.1M
|
Health Technology
|
18.29%
|
O:
0.79%
H:
0.18%
C:
-0.83%
keytruda
fda
review
cancer
treatment
application
grants
plus
FDA Accepts for Priority Review Merck’s Supplemental New Drug Application for WELIREG® (belzutifan) in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)
Published:
2023-09-19
(Crawled : 12:00)
- biospace.com/
MRK
|
$127.0
0.1%
-1.21%
7.1M
|
Health Technology
|
17.79%
|
O:
-0.16%
H:
0.49%
C:
-0.27%
welireg
fda
drug
renal
review
cell
application
European Commission Expands Merck’s ERVEBO® [Ebola Zaire Vaccine, (rVSVΔG-ZEBOV-GP) live] Indication to Include Children 1 Year of Age and Older
Published:
2023-09-07
(Crawled : 12:00)
- biospace.com/
MRK
|
$127.0
0.1%
-1.21%
7.1M
|
Health Technology
|
19.26%
|
O:
0.39%
H:
1.66%
C:
0.96%
LUMO
|
$2.795
-0.18%
-0.18%
46K
|
Health Technology
|
-17.46%
|
O:
0.3%
H:
5.6%
C:
-0.74%
ervebo
children
year
Merck to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
Published:
2023-09-05
(Crawled : 12:00)
- biospace.com/
MS
|
News
0 d
|
$93.85
0.1%
0.0%
4.8M
|
Finance
|
9.33%
|
O:
0.01%
H:
0.0%
C:
0.0%
MRK
|
$127.0
0.1%
-1.21%
7.1M
|
Health Technology
|
15.62%
|
O:
-0.35%
H:
0.24%
C:
-1.78%
conference
merck
global
Merck Initiates Phase 3 Clinical Program for Oral PCSK9 Inhibitor Candidate MK-0616
Published:
2023-08-25
(Crawled : 12:00)
- biospace.com/
MRK
|
$127.0
0.1%
-1.21%
7.1M
|
Health Technology
|
16.03%
|
O:
0.45%
H:
0.35%
C:
0.25%
mk-0616
candidate
merck
program
Merck and Eisai Provide Update on Phase 3 LEAP-010 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Patients With Certain Types of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Published:
2023-08-25
(Crawled : 12:00)
- biospace.com/
MRK
|
$127.0
0.1%
-1.21%
7.1M
|
Health Technology
|
16.03%
|
O:
0.45%
H:
0.35%
C:
0.25%
leap-010
keytruda
merck
update
cell
trial
plus
LYNPARZA® (olaparib) Plus Abiraterone and Prednisone or Prednisolone Approved in Japan for the Treatment of BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer
Published:
2023-08-24
(Crawled : 12:00)
- biospace.com/
FNCTF
|
News
|
$11.16
-20.84%
130
|
Communications
|
1.64%
|
O:
1.28%
H:
0.0%
C:
0.0%
MRK
|
$127.0
0.1%
-1.21%
7.1M
|
Health Technology
|
14.11%
|
O:
-0.31%
H:
0.96%
C:
-1.35%
lynparza
japan
approved
cancer
treatment
plus
Merck Announces WELIREG® (belzutifan) Phase 3 LITESPARK-005 Trial Met Primary Endpoint of Progression-Free Survival in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma
Published:
2023-08-18
(Crawled : 12:00)
- biospace.com/
MRK
|
$127.0
0.1%
-1.21%
7.1M
|
Health Technology
|
16.6%
|
O:
0.05%
H:
0.49%
C:
0.21%
spark-005
welireg
renal
merck
cell
trial
U.S. FDA Approves Merck’s ERVEBO® (Ebola Zaire Vaccine, Live) for Use in Children 12 Months of Age and Older
Published:
2023-08-03
(Crawled : 12:00)
- biospace.com/
MRK
|
$127.0
0.1%
-1.21%
7.1M
|
Health Technology
|
20.15%
|
O:
-0.59%
H:
0.67%
C:
0.62%
LUMO
|
$2.795
-0.18%
-0.18%
46K
|
Health Technology
|
-14.94%
|
O:
3.05%
H:
0.0%
C:
-5.62%
ervebo
fda
children
Merck Announces Phase 3 KEYNOTE-756 Trial Met Primary Endpoint of Pathological Complete Response (pCR) Rate in Patients With High-Risk, Early-Stage ER+/HER2- Breast Cancer
Published:
2023-07-28
(Crawled : 12:00)
- biospace.com/
MRK
|
$127.0
0.1%
-1.21%
7.1M
|
Health Technology
|
20.64%
|
O:
0.15%
H:
1.16%
C:
0.86%
ynote-756
breast
merck
cancer
trial
response
Merck to Hold Second-Quarter 2023 Sales and Earnings Conference Call on Aug. 1
Published:
2023-06-29
(Crawled : 12:00)
- biospace.com/
MRK
|
$127.0
0.1%
-1.21%
7.1M
|
Health Technology
|
12.95%
|
O:
-0.17%
H:
1.45%
C:
1.15%
sales
conference
merck
Merck Provides Update on Phase 3 KEYNOTE-585 Trial in Locally Advanced Resectable Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma
Published:
2023-06-20
(Crawled : 12:00)
- biospace.com/
MRK
|
$127.0
0.1%
-1.21%
7.1M
|
Health Technology
|
16.17%
|
O:
-0.22%
H:
1.63%
C:
1.05%
ynote-585
merck
update
trial
← Previous
1
2
3
4
5
6
7
Next →
Gainers vs Losers
62%
38%
Top 10 Gainers
CSSE
4
|
$0.4323
183.85%
64.77%
220M
|
Consumer Services
BOF
|
$1.99
70.09%
41.21%
110M
|
ILAG
|
$0.51
6.03%
40.62%
1.7M
|
LICN
|
$0.941
68.04%
40.49%
15M
|
AMST
|
$3.31
65.5%
39.58%
70M
|
Technology Services
MTC
|
$3.615
61.38%
38.04%
9.3M
|
Technology Services
WIMI
|
$1.15
58.53%
36.92%
19M
|
Technology Services
AIH
|
$0.45
12.5%
30.92%
320K
|
Health Services
MULN
|
News
|
$3.78
38.46%
27.78%
13M
|
Information
RILY
|
$29.86
37.48%
27.26%
12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.